As on Thursday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) started slowly as it slid -3.39% to $0.84, before settling in for the price of $0.87 at the close. Taking a more long-term approach, ADAP posted a 52-week range of $0.42-$2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 134.88%. Meanwhile, its Annual Earning per share during the time was 10.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 45.72%. This publicly-traded company’s shares outstanding now amounts to $227.17 million, simultaneously with a float of $226.31 million. The organization now has a market capitalization sitting at $215.17 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0374, while the 200-day Moving Average is $1.1311.
Adaptimmune Therapeutics Plc ADR (ADAP) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Adaptimmune Therapeutics Plc ADR’s current insider ownership accounts for 11.49%, in contrast to 48.83% institutional ownership. According to the most recent insider trade that took place on Jun 18 ’24, this organization’s Chief Commercial Officer sold 24,531 shares at the rate of 0.93, making the entire transaction reach 22,814 in total value, affecting insider ownership by 38,293. Preceding that transaction, on Jan 17 ’24, Company’s Chief Executive Officer sold 30,080 for 0.67, making the whole transaction’s value amount to 20,244. This particular insider is now the holder of 44,848 in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Revenue Records
Adaptimmune Therapeutics Plc ADR’s EPS increase for this current 12-month fiscal period is 45.72% and is forecasted to reach -0.11 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.00% through the next 5 years, which can be compared against the 10.30% growth it accomplished over the previous five years trading on the market.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Let’s observe the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). It’s Quick Ratio in the last reported quarter now stands at 3.09. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.52.
In the same vein, ADAP’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.35, a figure that is expected to reach -0.01 in the next quarter, and analysts are predicting that it will be -0.11 at the market close of one year from today.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Through scrutinizing the latest numbers posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], it can be observed that its last 5-days Average volume of 1.27 million was lower the volume of 1.68 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 25.64% While, its Average True Range was 0.0480.
Raw Stochastic average of Adaptimmune Therapeutics Plc ADR (ADAP) in the period of the previous 100 days is set at 2.52%, which indicates a major fall in contrast to 6.76% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.04% that was lower than 79.30% volatility it exhibited in the past 100-days period.
